ATE230740T1 - Piperidinylpyrimidine derivate - Google Patents
Piperidinylpyrimidine derivateInfo
- Publication number
- ATE230740T1 ATE230740T1 AT97916641T AT97916641T ATE230740T1 AT E230740 T1 ATE230740 T1 AT E230740T1 AT 97916641 T AT97916641 T AT 97916641T AT 97916641 T AT97916641 T AT 97916641T AT E230740 T1 ATE230740 T1 AT E230740T1
- Authority
- AT
- Austria
- Prior art keywords
- piperidinylpyrimidines
- derivatives
- alkyl
- secretion
- carbonyl
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 102000003390 tumor necrosis factor Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11555696 | 1996-04-12 | ||
| US72254896A | 1996-09-27 | 1996-09-27 | |
| PCT/JP1997/001240 WO1997038992A1 (en) | 1996-04-12 | 1997-04-10 | Piperidinylpyramidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE230740T1 true ATE230740T1 (de) | 2003-01-15 |
Family
ID=26454049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97916641T ATE230740T1 (de) | 1996-04-12 | 1997-04-10 | Piperidinylpyrimidine derivate |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0892795B1 (de) |
| JP (1) | JP2001511764A (de) |
| AT (1) | ATE230740T1 (de) |
| AU (1) | AU2521597A (de) |
| CA (1) | CA2250943A1 (de) |
| DE (1) | DE69718306D1 (de) |
| WO (1) | WO1997038992A1 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6410729B1 (en) | 1996-12-05 | 2002-06-25 | Amgen Inc. | Substituted pyrimidine compounds and methods of use |
| US6096753A (en) | 1996-12-05 | 2000-08-01 | Amgen Inc. | Substituted pyrimidinone and pyridone compounds and methods of use |
| US6498163B1 (en) | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
| KR20000070751A (ko) * | 1997-02-05 | 2000-11-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 세포 증식 억제제로서의 피리도[2,3-ｄ]피리미딘 및 4-아미노피리미딘 |
| SE9701509D0 (sv) * | 1997-04-22 | 1997-04-22 | Ericsson Telefon Ab L M | Method of routing a short message in a packet data network |
| IL149250A0 (en) * | 1999-10-22 | 2002-11-10 | Sanofi Synthelabo | Phenyl-and pyridyl-tetrahydro-pyridines having tnf inhibiting activity |
| US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| MXPA02010993A (es) * | 2000-05-12 | 2003-03-10 | Genzyme Corp | Reguladores de transmision de la tnf-alfa. |
| EP2404603A1 (de) | 2000-10-23 | 2012-01-11 | Glaxosmithkline LLC | Neue trisubstitutierte 8H-Pyrido[2,3-d]pyrimidin-7-Onderivate zur Behandlung von durch CSBP/p38kinase vermittelten Krankheiten |
| ATE314370T1 (de) | 2002-01-22 | 2006-01-15 | Warner Lambert Co | 2-(pyridin-2-ylamino)-pyrido(2,3-d)pyrimidin-7- one |
| MXPA04010267A (es) | 2002-04-19 | 2005-02-03 | Smithkline Beecham Corp | Compuestos novedosos. |
| EP1602655A4 (de) | 2003-03-07 | 2010-06-09 | Kowa Co | Benzofuranderivat |
| BRPI0412808A (pt) * | 2003-07-24 | 2006-09-26 | Euro Celtique Sa | compostos de piperidina e composições farmacêuticas contendo os mesmos |
| EP1865959A2 (de) | 2005-03-25 | 2007-12-19 | Glaxo Group Limited | Verfahren zur herstellung von pyrido¦2,3-d pyrimidin-7-on and 3,4-dihydropyrimido¦4,5-d pyrimidin-2(1h)-on-derivaten |
| PE20061351A1 (es) | 2005-03-25 | 2007-01-14 | Glaxo Group Ltd | COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38 |
| US20090137550A1 (en) | 2005-03-25 | 2009-05-28 | Glaxo Group Limited | Novel Compounds |
| TW200724142A (en) | 2005-03-25 | 2007-07-01 | Glaxo Group Ltd | Novel compounds |
| US8071768B2 (en) | 2005-06-10 | 2011-12-06 | Janssen Pharmaceutica, N.V. | Alkylquinoline and alkylquinazoline kinase modulators |
| US7825244B2 (en) | 2005-06-10 | 2010-11-02 | Janssen Pharmaceutica Nv | Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis |
| US8133901B2 (en) * | 2006-12-01 | 2012-03-13 | Actelion Pharmaceuticals Ltd. | 3-heteroaryl (amino or amido)-1-(biphenyl or phenylthiazolyl) carbonylpiperidine derivatives as orexin receptor inhibitors |
| JP5807971B2 (ja) * | 2009-04-27 | 2015-11-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｘｃｒ３受容体アンタゴニスト |
| US11542248B2 (en) * | 2017-06-08 | 2023-01-03 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| CN117800969B (zh) * | 2023-09-19 | 2024-11-29 | 武汉厚先生物医药有限公司 | 肿瘤坏死因子受体复合物抑制剂及其用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5976082A (ja) * | 1982-10-23 | 1984-04-28 | Kyowa Hakko Kogyo Co Ltd | 新規なピペリジン誘導体 |
-
1997
- 1997-04-10 JP JP53693897A patent/JP2001511764A/ja active Pending
- 1997-04-10 WO PCT/JP1997/001240 patent/WO1997038992A1/en not_active Ceased
- 1997-04-10 EP EP97916641A patent/EP0892795B1/de not_active Expired - Lifetime
- 1997-04-10 CA CA002250943A patent/CA2250943A1/en not_active Abandoned
- 1997-04-10 AU AU25215/97A patent/AU2521597A/en not_active Abandoned
- 1997-04-10 AT AT97916641T patent/ATE230740T1/de not_active IP Right Cessation
- 1997-04-10 DE DE69718306T patent/DE69718306D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001511764A (ja) | 2001-08-14 |
| AU2521597A (en) | 1997-11-07 |
| CA2250943A1 (en) | 1997-10-23 |
| EP0892795A1 (de) | 1999-01-27 |
| EP0892795B1 (de) | 2003-01-08 |
| WO1997038992A1 (en) | 1997-10-23 |
| DE69718306D1 (de) | 2003-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69718306D1 (de) | Piperidinylpyrimidine derivate | |
| NO985711D0 (no) | Farmas°ytikum for behandling av neurologiske og neuropsykiatriske mangler | |
| RU2088589C1 (en) | Derivatives of 17 beta-substituted-4-aza-5-5 alpha-androstane-3-ones, methods of synthesis of compounds, pharmaceutical composition, compound 4 | |
| MY141457A (en) | 4-mercaptopyrrolidine derivates a farnesyl transferase inhibitors | |
| ATE194335T1 (de) | 4,5-diaryloxazol-derivate | |
| MXPA02011974A (es) | Derivados de quinazolina sustituidos y su uso como inhibidores. | |
| IL120584A0 (en) | 1,2-diphenylpyrrole derivatives and pharmaceutical compositions containing the same | |
| BG101250A (en) | Salts of an anti-migraine indole derivative | |
| MY133473A (en) | Haterocyclic glycyl beta-alanine derivatives. | |
| HU914153D0 (en) | Electrically operated lock | |
| IT1250749B (it) | Composti eterociclici ad attivita' a ii antagonista | |
| WO2000039083A3 (en) | Pyrazole compounds and uses thereof | |
| DE69907419D1 (en) | Antitumorwirkstoffe | |
| NO943873D0 (no) | Hemming av bruskdegradering | |
| AU4023093A (en) | Novel substituted tertiary amino compound or salt thereof | |
| DE69418744D1 (de) | Verwendung von Pregnanderivaten zur Behandlung von Tumoren | |
| FI935799A0 (fi) | Arylsubstituerade heterocykliska foereningar | |
| ATE149159T1 (de) | Heteroarylmethylbenzole-aromatasehemmer | |
| HUP9802348A2 (hu) | 2-Fenil-3-aroil-benzotiofének alkalmazása plazminogén aktivátor inhibitor-1 gátló hatású gyógyszerkészítmények előállítására | |
| SE9704770D0 (sv) | New use | |
| ATE248163T1 (de) | Neuartige, pharmazeutisch aktive verbindung | |
| DE69528984D1 (de) | Hemmung der leukotrienbiosynthese mittels harnstoffderivaten | |
| HUP9801327A2 (hu) | Benzotiofénszármazékok felhasználása a petefészekrák gátlására alkalmas gyógyszerkészítmények előállítására | |
| DE69619088D1 (de) | Quinoxalin-Derivate zur Behandlung von Tinnitus | |
| MX9703610A (es) | Nuevas (5,6)-heteroaril condensado-pirimidin-4-onas 2,3 disustituidas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |